Addex Therapeutics Ltd (ADXN)
Automate Your Wheel Strategy on ADXN
With Tiblio's Option Bot, you can configure your own wheel strategy including ADXN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ADXN
- Rev/Share 0.2257
- Book/Share 10.0032
- PB 0.7559
- Debt/Equity 0.0053
- CurrentRatio 2.31
- ROIC -0.3269
- MktCap 5799373.1505
- FreeCF/Share -1.9998
- PFCF -4.0219
- PE -0.9012
- Debt/Assets 0.0045
- DivYield 0
- ROE -0.6676
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Addex Therapeutics Ltd (ADXN) Q2 2025 Earnings Call Transcript
Published: October 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Addex Therapeutics Ltd (NASDAQ:ADXN ) Q2 2025 Earnings Call October 1, 2025 10:00 AM EDT Company Participants Timothy Dyer - Co-Founder, CEO & Director Mikhail Kalinichev - Head of Translational Science Conference Call Participants Bob Pooler - ValuationLAB AG Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good day, and thank you for standing by.
Read More
Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update
Published: September 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
Cash position of CHF 2.3 million at end of H1 2025 GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to phase 2 mGlu2 PAM asset, ADX71149 Indivior advanced GABAB PAM substance use disorders program successfully through IND enabling studies Entered option agreement with Sinntaxis for exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recovery Invested in Stalicla SA, confirming commitment to advancing innovative treatments for CNS disorders Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 30, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a …
Read More
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 6, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) in multiple preclinical models of chronic cough compared to reference drugs.
Read More
Addex Convenes Annual General Meeting 2025
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
Geneva, Switzerland, June 3, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its 2025 Annual General Meeting will take place on Tuesday June 24, 2025, at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva (doors open at 10:30 am).
Read More
Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 12, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today partner Indivior has successfully advanced its GABAB positive allosteric modulator (PAM) program through IND enabling studies.
Read More
Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 30, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that it has entered into an option- and collaboration agreement with Sinntaxis AB (www.sinntaxis.com) for an exclusive license to intellectual property covering the use of metabotropic glutamate receptor subtype 5 (mGlu5) inhibitors for the treatment of brain injury recovery.
Read More
About Addex Therapeutics Ltd (ADXN)
- IPO Date 2020-02-12
- Website https://www.addextherapeutics.com
- Industry Biotechnology
- CEO Timothy Mark Dyer
- Employees 2